about
Analysis of Genetic Variation in CYP450 Genes for Clinical ImplementationThe Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian SubjectsClinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosingTopical phenytoin for the treatment of neuropathic pain.CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers.Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population.Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior.CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children.Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects.Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?Variation in CYP2A6 Activity and Personalized Medicine.Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions.CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment.
P2860
Q28468449-1C69C6B5-6C3F-4251-94CD-6C31ADF5D57BQ28547386-C3B4545A-0724-455D-A9B6-273B38F1B0B1Q34389432-40C2907C-5817-4188-880E-E62514CDC398Q37682828-D03E7DC6-6111-4A32-9235-72CF03963F5AQ38513684-753DDE1A-E294-4334-A571-394D8E42E825Q38651234-B1FA3A52-B60E-4B20-919A-75673DD68DB8Q38803195-C4F7983B-014B-4754-91DE-0C293781C0ADQ39065445-E6126F72-358B-4D8A-8975-840139B9EE02Q40554461-57CA87FD-4645-423F-8607-F70BDDBC93F0Q41631036-4512C0FF-BA17-44F5-A20C-AA69B7E74560Q41725845-3FADC08F-4271-4A9F-93F6-41F87072A5AEQ42098029-62B262D9-9E9C-4218-9A65-0DA52AD7E04EQ46664880-978B1E1F-6ED5-48E7-B703-4E4529BBD96CQ47163198-3EF09940-4CD3-4BF1-B4EC-B4E3A3D6311EQ53782592-23135708-A926-4E3A-A1E6-FC49582B1A88Q55017266-9568FA11-CC7B-45C3-8E5A-510D8B0DAAF3
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
PharmGKB summary: phenytoin pathway.
@ast
PharmGKB summary: phenytoin pathway.
@en
type
label
PharmGKB summary: phenytoin pathway.
@ast
PharmGKB summary: phenytoin pathway.
@en
prefLabel
PharmGKB summary: phenytoin pathway.
@ast
PharmGKB summary: phenytoin pathway.
@en
P2093
P2860
P1476
PharmGKB summary: phenytoin pathway.
@en
P2093
Caroline F Thorn
J Steven Leeder
Michelle Whirl-Carrillo
Teri E Klein
P2860
P304
P356
10.1097/FPC.0B013E32834AEEDB
P577
2012-06-01T00:00:00Z